3K7A Stock Overview
A psychedelics and wellness company, develops psychedelic medicine to reduce trauma.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Silo Wellness Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.0005 |
52 Week High | CA$0.018 |
52 Week Low | CA$0.0001 |
Beta | 0.66 |
11 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -96.67% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
3K7A | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -1.7% | -1.8% |
1Y | -96.7% | -12.7% | 13.2% |
Return vs Industry: 3K7A underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 3K7A underperformed the German Market which returned 5.9% over the past year.
Price Volatility
3K7A volatility | |
---|---|
3K7A Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 7.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3K7A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 3K7A's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Mike Arnold | www.silowellness.com |
Silo Wellness Inc., a psychedelics and wellness company, develops psychedelic medicine to reduce trauma. The company develops and sells psilocybin-free functional mushroom tinctures; and the formulation of a psilocybin nasal spray in Jamaica. It also offers a portfolio of functional mushroom products: Jamaican and Oregon psychedelic wellness retreats.
Silo Wellness Inc. Fundamentals Summary
3K7A fundamental statistics | |
---|---|
Market cap | €1.04m |
Earnings (TTM) | €466.92k |
Revenue (TTM) | €252.08k |
2.2x
P/E Ratio4.1x
P/S RatioIs 3K7A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3K7A income statement (TTM) | |
---|---|
Revenue | US$275.89k |
Cost of Revenue | US$180.23k |
Gross Profit | US$95.66k |
Other Expenses | -US$415.36k |
Earnings | US$511.02k |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.0033 |
Gross Margin | 34.67% |
Net Profit Margin | 185.23% |
Debt/Equity Ratio | -47.5% |
How did 3K7A perform over the long term?
See historical performance and comparison